In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) closed at $0.73 in the last session, up 6.62% from day before closing price of $0.68. In other words, the price has increased by $6.62 from its previous closing price. On the day, 3.31 million shares were traded. ADAP stock price reached its highest trading level at $0.7309 during the session, while it also had its lowest trading level at $0.6819.
Ratios:
We take a closer look at ADAP’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.82 and its Current Ratio is at 3.85. In the meantime, Its Debt-to-Equity ratio is 0.93 whereas as Long-Term Debt/Eq ratio is at 0.88.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on July 30, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On May 30, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $3.15.
On March 24, 2023, Bryan Garnier started tracking the stock assigning a Buy rating and target price of $3.60.Bryan Garnier initiated its Buy rating on March 24, 2023, with a $3.60 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 18 ’24 when Piccina Cintia sold 24,531 shares for $0.93 per share. The transaction valued at 22,814 led to the insider holds 38,293 shares of the business.
Rawcliffe Adrian sold 30,080 shares of ADAP for $20,244 on Jan 17 ’24. The Chief Executive Officer now owns 44,848 shares after completing the transaction at $0.67 per share. On Jan 16 ’24, another insider, Rawcliffe Adrian, who serves as the Chief Executive Officer of the company, sold 9,304 shares for $0.79 each. As a result, the insider received 7,350 and left with 14,104 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADAP now has a Market Capitalization of 185515184 and an Enterprise Value of 739739264. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.06 while its Price-to-Book (P/B) ratio in mrq is 2.32. Its current Enterprise Value per Revenue stands at 5.229 whereas that against EBITDA is -10.15.
Stock Price History:
Over the past 52 weeks, ADAP has reached a high of $2.05, while it has fallen to a 52-week low of $0.42. The 50-Day Moving Average of the stock is -10.81%, while the 200-Day Moving Average is calculated to be -34.38%.
Shares Statistics:
According to the various share statistics, ADAP traded on average about 1.46M shares per day over the past 3-months and 3661780 shares per day over the past 10 days. A total of 227.17M shares are outstanding, with a floating share count of 226.31M. Insiders hold about 11.49% of the company’s shares, while institutions hold 47.98% stake in the company. Shares short for ADAP as of 1730332800 were 5349350 with a Short Ratio of 4.74, compared to 1727654400 on 6086908. Therefore, it implies a Short% of Shares Outstanding of 5349350 and a Short% of Float of 3.1400003.
Earnings Estimates
Currently, 4.0 analysts are dedicated to thoroughly evaluating and rating the performance of Adaptimmune Therapeutics Plc ADR (ADAP) in the stock market.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.15 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.04 and -$0.2 for the fiscal current year, implying an average EPS of -$0.15. EPS for the following year is -$0.49, with 4.0 analysts recommending between -$0.37 and -$0.59.
Revenue Estimates
For the next quarter, 9 analysts are estimating revenue of $6.3M. There is a high estimate of $7.3M for the next quarter, whereas the lowest estimate is $4.4M.
A total of 7 analysts have provided revenue estimates for ADAP’s current fiscal year. The highest revenue estimate was $205.1M, while the lowest revenue estimate was $174.81M, resulting in an average revenue estimate of $183.8M. In the same quarter a year ago, actual revenue was $60.28MBased on 9 analysts’ estimates, the company’s revenue will be $39.9M in the next fiscal year. The high estimate is $55.99M and the low estimate is $15.86M.
